company background image
513 logo

Livzon Pharmaceutical Group SZSE:000513 Stock Report

Last Price

CN¥39.03

Market Cap

CN¥32.0b

7D

-2.2%

1Y

-2.4%

Updated

13 Jun, 2024

Data

Company Financials +

Livzon Pharmaceutical Group Inc.

SZSE:000513 Stock Report

Market Cap: CN¥32.0b

513 Stock Overview

Researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China.

513 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance4/6
Financial Health5/6
Dividends5/6

Livzon Pharmaceutical Group Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Livzon Pharmaceutical Group
Historical stock prices
Current Share PriceCN¥39.03
52 Week HighCN¥41.47
52 Week LowCN¥31.72
Beta0.21
1 Month Change-3.91%
3 Month Change1.64%
1 Year Change-2.45%
3 Year Change-18.69%
5 Year Change63.15%
Change since IPO3,846.43%

Recent News & Updates

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Jun 07
We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 26
Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Apr 21
Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Recent updates

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Jun 07
We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 26
Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Apr 21
Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Mar 15
Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Shareholder Returns

513CN PharmaceuticalsCN Market
7D-2.2%-0.8%-0.9%
1Y-2.4%-9.9%-14.4%

Return vs Industry: 000513 exceeded the CN Pharmaceuticals industry which returned -9.9% over the past year.

Return vs Market: 000513 exceeded the CN Market which returned -14.4% over the past year.

Price Volatility

Is 513's price volatile compared to industry and market?
513 volatility
513 Average Weekly Movement2.8%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.1%
10% least volatile stocks in CN Market4.1%

Stable Share Price: 000513 has not had significant price volatility in the past 3 months.

Volatility Over Time: 000513's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19858,933Yanggang Tangwww.livzon.com.cn

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precocious puberty; and Urofollitropin for injection to treat anovulation and sufferers. It also provides Perospirone hydrochloride tablets to treat schizophrenia; Shenqi Fuzheng Injection to treat weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for treating lung and stomach cancer; anti-viral granules used for clearing heat, eliminating dampness, cooling blood, and detoxifying to treat upper respiratory tract infection and influenza; Tocilizumab injection to treat rheumatoid arthritis; and Recombinant SARSCoV-2 fusion protein vaccine used to prevent diseases caused by SARS-CoV-2 infection.

Livzon Pharmaceutical Group Inc. Fundamentals Summary

How do Livzon Pharmaceutical Group's earnings and revenue compare to its market cap?
513 fundamental statistics
Market capCN¥31.96b
Earnings (TTM)CN¥1.98b
Revenue (TTM)CN¥12.26b

18.2x

P/E Ratio

2.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
513 income statement (TTM)
RevenueCN¥12.26b
Cost of RevenueCN¥4.66b
Gross ProfitCN¥7.60b
Other ExpensesCN¥5.62b
EarningsCN¥1.98b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)2.14
Gross Margin62.01%
Net Profit Margin16.15%
Debt/Equity Ratio23.0%

How did 513 perform over the long term?

See historical performance and comparison

Dividends

3.5%

Current Dividend Yield

63%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.